The story of living in spite of melanoma, metastasis, vaccines, anti-PD-1, lung removal, and stereotactic radiation. The story of life with family and friends. {Posts under ~ Sew Chaotically, Travel Chaotically, and Chaotic Cookery also housed within! A girl's gotta have fun!}

About Me

Who am I? That is a question the rest of you could probably answer better than I. I am a wife, mother, daughter, sister, friend, pediatric nurse practitioner, cook, teacher, gardener, lover of words and music, occasional seamstress, and homemaker. I do have a couple of talents of questionable merit: I can create a decent meal in less than 30 minutes. I can feed and/or soothe almost any baby. And I can remember practically any song I've ever heard. For the rest, I'd rather those who know me decide.

Among the 655 patients (median [range] age, 61 [18-94] years; 405 [62%]
men), 581 had measurable disease at baseline. An objective response was
reported in 194 of 581 patients (33%) and in 60 of 133 treatment-naive patients
(45%). Overall, 74% (152/205) of responses were ongoing at the time of data
cutoff; 44% (90/205) of patients had response duration for at least 1 year and
79% (162/205) had response duration for at least 6 months. Twelve-month progression-free survival rates were 35% in the total population
and 52% among treatment-naive patients.Median overall survival in the total population was 23 months, with
a 12-month survival rate of 66%, and a 24-month survival rate of 49%. In treatment-naive patients, median overall
survival was 31 months, with a 12-month survival rate of 73%, and a 24-month survival rate of 60%.
Ninety-two of 655 patients (14%) experienced at least 1 treatment-related grade
3 or 4 adverse event (AE) and 27 of 655 (4%) patients discontinued treatment
because of a treatment-related AE. Treatment-related serious AEs were reported
in 59 patients (9%). There were no drug-related deaths.

Once again it is clear that treatment naive patients do better on anti-PD1 than those who are pretreated...particularly with ipi. Here is a post and link to the report from the Checkmate 064 trial in which folks
who got nivo first followed by ipi had slightly more side effects
(roughly 50 vs 43%) but they also had objective response rates of 41.2%
vs only 20% in the ipi first group!!!!!!!!!!!!!!!! - Sequential nivo then ipi vs Sequential ipi then nivoHere is a recent report on OS with nivo - Nivolumab shows impressive OS in melanomaThe data here is further out. All patients were "heavily pre-treated", so none were treatment naive, but none had been treated with ipi.We never can compare apples to apples, can we? But...still....good news overall! Way to go, Ratties! - c